Literature DB >> 22158567

Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines.

Lee M Hampton1, Monica M Farley, William Schaffner, Ann Thomas, Arthur Reingold, Lee H Harrison, Ruth Lynfield, Nancy M Bennett, Susan Petit, Kenneth Gershman, Joan Baumbach, Bernard Beall, James Jorgensen, Anita Glennen, Elizabeth R Zell, Matthew Moore.   

Abstract

BACKGROUND: Streptococcus pneumoniae (pneumococcus) caused approximately 44000 US invasive pneumococcal disease (IPD) cases in 2008. Antibiotic nonsusceptibility complicates IPD treatment. Using penicillin susceptibility breakpoints adopted in 2008, we evaluated antibiotic-nonsusceptible IPD trends in light of the introductions of a 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 and a 13-valent pneumococcal conjugate vaccine (PCV13) in 2010.
METHODS: IPD cases were defined by isolation of pneumococcus from a normally sterile site in individuals residing in Active Bacterial Core surveillance (ABCs) areas during 1998-2008. Pneumococci were serotyped and tested for antibiotic susceptibility using broth microdilution.
RESULTS: During 1998-2008, ABCs identified 43198 IPD cases. Penicillin-nonsusceptible strains caused 6%-14% of IPD cases, depending on age. Between 1998-1999 and 2008, penicillin-nonsusceptible IPD rates declined 64% for children aged <5 years (12.1-4.4 cases per 100000), and 45% for adults aged ≥65 (4.8-2.6 cases per 100000). Rates of IPD nonsusceptible to multiple antibiotics mirrored these trends. During 2007-2008, serotypes in PCV13 but not PCV7 caused 78%-97% of penicillin-nonsusceptible IPD, depending on age.
CONCLUSIONS: Antibiotic-nonsusceptible IPD rates remain below pre-PCV7 rates for children <5 and adults ≥65 years old. PCV13 vaccines hold promise for further nonsusceptibility reductions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22158567     DOI: 10.1093/infdis/jir755

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  45 in total

1.  Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States.

Authors:  Ruth Link-Gelles; Ann Thomas; Ruth Lynfield; Sue Petit; William Schaffner; Lee Harrison; Monica M Farley; Deborah Aragon; Megin Nicols; Pam Daily Kirley; Shelley Zansky; James Jorgensen; Billie Anne Juni; Delois Jackson; Matthew R Moore; Marc Lipsitch
Journal:  J Infect Dis       Date:  2013-07-12       Impact factor: 5.226

2.  Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines.

Authors:  Carmen Muñoz-Almagro; Adoracion Navarro-Torne; Roman Pallares
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

3.  Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008.

Authors:  Penny Crowther-Gibson; Cheryl Cohen; Keith P Klugman; Linda de Gouveia; Anne von Gottberg
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

4.  Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents.

Authors:  Rodrigo E Mendes; Donald Biek; Ian A Critchley; David J Farrell; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 5.  The role of vaccines in preventing bacterial antimicrobial resistance.

Authors:  Kathrin U Jansen; Charles Knirsch; Annaliesa S Anderson
Journal:  Nat Med       Date:  2018-01-09       Impact factor: 53.440

6.  Antibiotic Choice for Children Hospitalized With Pneumonia and Adherence to National Guidelines.

Authors:  Derek J Williams; Kathryn M Edwards; Wesley H Self; Yuwei Zhu; Krow Ampofo; Andrew T Pavia; Adam L Hersh; Sandra R Arnold; Jonathan A McCullers; Lauri A Hicks; Anna M Bramley; Seema Jain; Carlos G Grijalva
Journal:  Pediatrics       Date:  2015-07       Impact factor: 7.124

Review 7.  Risk Factors for Drug-Resistant Cap in Immunocompetent Patients.

Authors:  Francisco Arancibia; Mauricio Ruiz
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

8.  Decrease in antibiotic use, an added benefit of PCVs.

Authors:  Carlos G Grijalva
Journal:  Lancet Infect Dis       Date:  2013-11-26       Impact factor: 25.071

9.  Quantitative Proteomics of the 2016 WHO Neisseria gonorrhoeae Reference Strains Surveys Vaccine Candidates and Antimicrobial Resistance Determinants.

Authors:  Fadi E El-Rami; Ryszard A Zielke; Teodora Wi; Aleksandra E Sikora; Magnus Unemo
Journal:  Mol Cell Proteomics       Date:  2018-10-23       Impact factor: 5.911

10.  Racial and Regional Differences in Rates of Invasive Pneumococcal Disease.

Authors:  Annabelle de St Maurice; Carlos G Grijalva; Christopher Fonnesbeck; William Schaffner; Natasha B Halasa
Journal:  Pediatrics       Date:  2015-10-12       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.